Arrivent Biopharma Inc (AVBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -59,855 | -39,291 | -17,417 | -69,333 | -48,140 |
| Accounts payable and accrued liabilities | 114 | -720 | -374 | 1,379 | 1,084 |
| Other Working Capital | 3,539 | 186 | -1,836 | 12,596 | 6,635 |
| Other Operating Activity | 2,142 | 2,110 | 999 | -484 | -508 |
| Operating Cash Flow | $-54,060 | $-37,715 | $-18,628 | $-55,842 | $-40,929 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | N/A | N/A | -25,000 |
| Investing Cash Flow | $N/A | $N/A | $N/A | $0 | $-25,000 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 186,526 | 185,995 | 185,632 | 354 | 69 |
| Other Financing Activity | 0 | 0 | 0 | 42,505 | 43,847 |
| Financing Cash Flow | $186,526 | $185,995 | $185,632 | $42,859 | $43,916 |
| Beginning Cash Position | 150,389 | 150,389 | 150,389 | 163,372 | 163,372 |
| End Cash Position | 282,855 | 298,669 | 317,393 | 150,389 | 141,359 |
| Net Cash Flow | $132,466 | $148,280 | $167,004 | $-12,983 | $-22,013 |
| Free Cash Flow | |||||
| Operating Cash Flow | -54,060 | -37,715 | -18,628 | -55,842 | -40,929 |
| Free Cash Flow | -54,060 | -37,715 | -18,628 | -55,842 | -40,929 |